Stock ANTX AN2 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.015 USD -1.23% Intraday chart for AN2 Therapeutics, Inc. -0.25% -90.17%
May. 16 Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating MT
May. 14 AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on AN2 Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8bf5e91722297ad10291d5.VQydnn1LpFQkSVbzzHzvdkOO40wUbSphNoj1R9Kqjbg.Gn3P9CIB1TtHJy6ruQ-_NCbbuSl_NGcIBN-GIKLDxNM3QerWBAGTMW8LHw~53636c99ff62468cb16adb69675279dc

Analyst Recommendations on AN2 Therapeutics, Inc.

Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating MT
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform MT
Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23 MT
Oppenheimer Downgrades AN2 Therapeutics to Market Perform From Outperform MT
Evercore ISI Downgrades AN2 Therapeutics to In Line from Outperform, Adjusts PT to $7 From $25 MT
JMP Securities Downgrades AN2 Therapeutics to Market Perform From Market Outperform MT
JMP Securities Initiates AN2 Therapeutics With Market Outperform Rating, Price Target is $30 MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $27 From $24, Maintains Outperform Rating MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $24 From $20, Maintains Outperform Rating MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $20 From $22, Maintains Outperform Rating MT
Evercore ISI Initiates Coverage on AN2 Therapeutics With Outperform Rating, $25 Price Target MT
Oppenheimer Initiates Coverage on AN2 Therapeutics With Outperform Rating, $22 Price Target MT
Cowen Starts AN2 Therapeutics at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.99 USD
Average target price
4.333 USD
Spread / Average Target
+117.76%
High Price Target
6 USD
Spread / Highest target
+201.51%
Low Price Target
2 USD
Spread / Lowest Target
+0.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AN2 Therapeutics, Inc.

Evercore ISI
JMP Securities
Leerink Partners
Oppenheimer
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANTX Stock
  4. Consensus AN2 Therapeutics, Inc.